Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

NCT03242915 PHASE2 COMPLETED Results posted

Investigators hypothesize that addition of pembrolizumab will enhance the efficacy of carboplatin and pemetrexed in patients with EGFR-mutation-positive NSCLC, or patients with other genetic alterations, and who have disease progression following appropriate targeted therapies.

Details

Lead sponsor	University of Michigan Rogel Cancer Center
Phase	PHASE2
Status	COMPLETED
Enrolment	33
Start date	Tue Oct 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Feb 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Non-small Cell Lung Cancer

Interventions

• Pembrolizumab
• Carboplatin
• Pemetrexed

Countries

United States